Arcus Biosciences Officer Prepares 5,000-Share Sale Under Scheduled Trading Plan

An Arcus Biosciences executive, Robert C. Goeltz II, has signaled intent to sell a portion of his common stock under Rule 144, continuing insider trading activity observed over recent months. The notice outlines a scheduled disposal of 5,000 shares, routed through a brokerage in San Francisco and designated for execution on or near November 26, 2025 via the New York Stock Exchange.

The estimated value of the pending sale is $125,000, based on figures provided in the disclosure. The filing identifies Goeltz as an officer of Arcus Biosciences and attributes the shares to equity-based awards granted in previous years rather than market-purchased securities.

The shares originate from compensation grants issued in December 2022 and December 2023. The earlier award accounts for 2,061 shares, while the latter supplied 2,939 shares, both categorized as company-issued stock incentives. Neither award was labeled as a gift, and acquisition dates match payment dates tied to compensation events.

The disclosure also references a prior sale of 5,000 shares completed on October 28, 2025, which generated gross proceeds of roughly $100,000. If the newly planned sale is executed, insider dispositions within the quarter would total 10,000 shares. The notice affirms usage of a Rule 10b5-1 trading plan, adopted in March 2023 and modified in February 2024, providing structured timing for trades independent of near-term corporate developments.

By submitting the document, the reporting officer confirmed awareness of no undisclosed adverse operational information affecting Arcus Biosciences. The planned sale, grounded in equity compensation cycles and formal trading schedules, reflects a common mechanism for executives to realize value while retaining regulatory safeguards and market transparency.